{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:10:57Z","timestamp":1780967457092,"version":"3.54.1"},"reference-count":48,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Pathophysiological variability in patients with cancer is associated with differences in responses to pharmacotherapy. In this work, we aimed to describe the demographic characteristics and hematological, biochemical, and coagulation variables in a large oncology cohort and to develop, optimize, and provide open access to modeling equations for the estimation of variables potentially relevant in pharmacokinetic modeling. Methods: Using data from 1793 patients with cancer, divided into training (n = 1259) and validation (n = 534) datasets, a modeling network was developed and used to simulate virtual oncology populations. All analyses were conducted in RStudio 4.3.2 Build 494. Results: The simulation network based on sex, age, biogeographic origin\/ethnicity, and tumor type (fixed or primary factors) was successfully validated, able to predict age, height, weight, alpha-1-acid glycoprotein, albumin, hemoglobin, C-reactive protein and lactate dehydrogenase serum levels, platelet\u2013lymphocyte and neutrophil\u2013lymphocyte ratios, and hematocrit. This network was then successfully extrapolated to simulate the laboratory variables of eight oncology populations (n = 1200); only East Asians, Sub-Saharan Africans, Europeans, only males, females, patients with an ECOG performance status equal to 2, and only patients with pancreas cancer or ovarian cancer. Conclusions: this network constitutes a valuable tool to predict relevant characteristics\/variables of patients with cancer, which may be useful in the evaluation and prediction of pharmacokinetics in virtual oncology populations, as well as for model-based optimization of oncology treatments.<\/jats:p>","DOI":"10.3390\/pharmaceutics16121548","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:18:32Z","timestamp":1733217512000},"page":"1548","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Description and Modeling of Relevant Demographic and Laboratory Variables in a Large Oncology Cohort to Generate Virtual Populations"],"prefix":"10.3390","volume":"16","author":[{"given":"Laura","family":"P\u00e9rez-Ramos","sequence":"first","affiliation":[{"name":"PharmaMar S.A., Clinical Pharmacology Department, Clinical Development, 28770 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ibarra-G\u00f3mez","sequence":"additional","affiliation":[{"name":"PharmaMar S.A., Clinical Pharmacology Department, Clinical Development, 28770 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-8228","authenticated-orcid":false,"given":"Rubin","family":"Lubomirov","sequence":"additional","affiliation":[{"name":"PharmaMar S.A., Clinical Pharmacology Department, Clinical Development, 28770 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-1210","authenticated-orcid":false,"given":"Mar\u00eda","family":"Garc\u00eda-Cremades","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Institute of Industrial Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-6758","authenticated-orcid":false,"given":"Eduardo","family":"As\u00edn-Prieto","sequence":"additional","affiliation":[{"name":"PharmaMar S.A., Clinical Pharmacology Department, Clinical Development, 28770 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7320-6139","authenticated-orcid":false,"given":"Salvador","family":"Fudio","sequence":"additional","affiliation":[{"name":"PharmaMar S.A., Clinical Pharmacology Department, Clinical Development, 28770 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[{"name":"PharmaMar S.A., Clinical Pharmacology Department, Clinical Development, 28770 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejca.2006.10.015","article-title":"Pharmacokinetics in cancer chemotherapy","volume":"43","author":"Garattini","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2174\/1381612023393512","article-title":"Tissue transport of anti-cancer drugs","volume":"8","author":"Lankelma","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0009-9120(94)90032-9","article-title":"Effect of age and disease on two drug binding proteins: Albumin and alpha-1- acid glycoprotein","volume":"27","author":"Woo","year":"1994","journal-title":"Clin. Biochem."},{"key":"ref_4","first-page":"1","article-title":"Drug binding to human alpha-1-acid glycoprotein in health and disease","volume":"40","author":"Kremer","year":"1988","journal-title":"Pharmacol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2165\/00003088-198005030-00004","article-title":"Disease-induced changes in the plasma binding of basic drugs","volume":"5","author":"Piafsky","year":"1980","journal-title":"Clin. Pharmacokinet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1081\/DMR-100104402","article-title":"Human alpha-1-glycoprotein and its interactions with drugs","volume":"33","author":"Israili","year":"2001","journal-title":"Drug Metab. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1007\/s11095-015-1699-x","article-title":"Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques","volume":"32","author":"Teutonico","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40262-021-01072-4","article-title":"Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling","volume":"61","author":"Gerhart","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/bdd.1830","article-title":"A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer","volume":"34","author":"Cheeti","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/cpt.1322","article-title":"Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research","volume":"105","author":"Huddart","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1055-9965.EPI-20-0036","article-title":"Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis","volume":"29","author":"Dong","year":"2020","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Goldman, N., Glei, D.A., and Weinstein, M. (2016). What Matters Most for Predicting Survival? A Multinational Population-Based Cohort Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159273"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eaao5253","DOI":"10.1126\/scitranslmed.aao5253","article-title":"Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data","volume":"11","author":"Yang","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-002-0530-x","article-title":"Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities","volume":"58","author":"Kishino","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1159\/000503095","article-title":"Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1158\/1078-0432.CCR-12-2935","article-title":"The clinical viewpoint: Definitions, limitations of RECIST, practical considerations of measurement","volume":"19","author":"Villaruz","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Assayag, J., Kim, C., Chu, H., and Webster, J. (2023). The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: A systematic review and meta-analysis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1194718"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4014\/jmb.2006.06007","article-title":"Serum Levels and Glycosylation Changes of Alpha-1-Acid Glycoprotein According to Severity of Breast Cancer in Korean Women","volume":"30","author":"Choi","year":"2020","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1080\/21655979.2022.2036303","article-title":"Characterization of alpha-1-acid glycoprotein as a potential biomarker for breast cancer","volume":"13","author":"Qiong","year":"2022","journal-title":"Bioengineered"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s12325-022-02067-8","article-title":"Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers","volume":"39","author":"Zubiaur","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e235834","DOI":"10.1001\/jamanetworkopen.2023.5834","article-title":"Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US","volume":"6","author":"Shubeck","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","article-title":"Age and cancer risk: A potentially modifiable relationship","volume":"46","author":"White","year":"2014","journal-title":"Am. J. Prev. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","article-title":"What is the best size descriptor to use for pharmacokinetic studies in the obese?","volume":"58","author":"Green","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","first-page":"336","article-title":"Management of Weight Loss in People With Cancer","volume":"7","author":"Hager","year":"2016","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","article-title":"Albumin-based drug delivery: Harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol. Cell Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/clpt.1982.163","article-title":"Altered plasma drug binding in cancer: Role of alpha 1-acid glycoprotein and albumin","volume":"32","author":"Jackson","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17460441.2.1.51","article-title":"The importance of plasma protein binding in drug discovery","volume":"2","author":"Trainor","year":"2007","journal-title":"Expert. Opin. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11030-021-10186-7","article-title":"Predicting blood-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans","volume":"25","author":"Mamada","year":"2021","journal-title":"Mol. Divers."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Piletta-Zanin, A., De Mul, A., Rock, N., Lescuyer, P., Samer, C.F., and Rodieux, F. (2021). Case Report: Low Hematocrit Leading to Tacrolimus Toxicity. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.717148"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00228-019-02661-w","article-title":"Relationship between hemoglobin levels and vancomycin clearance in patients with sepsis","volume":"75","author":"Chuma","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00228-019-02724-y","article-title":"Is vancomycin clearance really correlated with hemoglobin? Arguments that it\u2019s not","volume":"75","author":"Deenen","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/hematolrep15020030","article-title":"Comparison of Two Methods of Capillary Sampling in Blood Pre-Donation Anemia Screening in Brazil","volume":"15","author":"Flor","year":"2023","journal-title":"Hematol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of LDH in cancer","volume":"19","author":"Claps","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_39","unstructured":"Farhana, A., and Lappin, S.L. (2024). Biochemistry, Lactate Dehydrogenase, StatPearls."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hart, P.C., Rajab, I.M., Alebraheem, M., and Potempa, L.A. (2020). C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.595835"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/00365517209080258","article-title":"The concentration of C-reactive protein in sera from healthy individuals","volume":"29","author":"Kindmark","year":"1972","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"French Society of Pharmacology and Therapeutics. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment","volume":"215","author":"Chhun","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3343\/alm.2019.39.4.345","article-title":"The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases","volume":"39","author":"Gasparyan","year":"2019","journal-title":"Ann. Lab. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111797","DOI":"10.1016\/j.mad.2023.111797","article-title":"Sex differences in markers of oxidation and inflammation. Implications for ageing","volume":"211","author":"Valera","year":"2023","journal-title":"Mech. Ageing Dev."},{"key":"ref_45","first-page":"606","article-title":"Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio are Predictors of Heart Failure","volume":"105","author":"Durmus","year":"2015","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_46","unstructured":"Food and Drug Administration, U.S. (2020). Enhancing the Diversity of Clinical Trial Populations\u2014Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry."},{"key":"ref_47","unstructured":"Food and Drug Administration, U.S. (2024). CDER Patient-Focused Drug Development."},{"key":"ref_48","unstructured":"Food and Drug Administration, U.S. (2024). Project Optimus."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/12\/1548\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:45:42Z","timestamp":1760114742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/12\/1548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["pharmaceutics16121548"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16121548","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]}}}